Mizuho Reiterates Buy on Fate Therapeutics, Raises Price Target to $33

Mizuho analyst Mara Goldstein reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $27 to $33.

Benzinga · 12/30/2019 11:28

Mizuho analyst Mara Goldstein reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $27 to $33.